• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » J&J Innovation launches JLABS @ TMC to catalyze early-stage research

J&J Innovation launches JLABS @ TMC to catalyze early-stage research

March 3, 2016
CenterWatch Staff

Johnson & Johnson Innovation has opened JLABS @ TMC, a new 34,000-square-foot life sciences incubator providing entrepreneurs shared lab space, private offices and modular laboratory suites, as well as state-of-the-art equipment and value-added operational, education and business services. The new JLABS facility can accommodate up to 50 startups, and will open with 21 companies that represent a range of disciplines and geographies. This first "class" of resident startups includes the four winners of the JLABS Quick Fire Challenge, which awards promising early-stage innovation companies with residency at the facility.

JLABS @ TMC builds on the successful JLABS model and is the fifth JLABS facility to open in the U.S. The Houston site is the first to open with a medical device prototype lab, including a 3-D printer, which will provide entrepreneurs access to highly specialized tools, as well as skills building programs to design and develop smart health technologies.

JLABS @ TMC is housed within the TMC Innovation Institute, adjacent to TMC's life sciences accelerator TMCx, enhancing its "think tank" –like environment and encouraging sharing of ideas, collaboration among JLABS, TMC and TMCx residents, and facilitation of relationships with investors and venture capitalists.

"We're thrilled to expand our JLABS initiative into Houston," said Paul Stoffels, M.D., chief scientific officer and worldwide chairman, Pharmaceuticals, Johnson & Johnson. "The city's rich research, academic and investment communities provide a robust ecosystem of early stage innovation, and present a unique opportunity to collaborate with Texas startups to deliver much-needed therapeutics, medical devices and consumer health solutions to patients and consumers more quickly."

"We have been eagerly awaiting this day when JLABS @ TMC opens its doors and immediately enhances our already robust ecosystem of talented entrepreneurs who are solving the greatest unmet healthcare needs of our generation," said Robert C. Robbins, M.D., president and CEO of the Texas Medical Center. "TMC has spent decades making healthcare history, and now these business accelerators housed at TMC will take innovation to new heights."

JLABS @ TMC joins a network of facilities that are based throughout North America in life science clusters, including San Diego (flagship), San Francisco, South San Francisco, Boston and, opening this spring, the first international location in Toronto, Canada. These facilities are currently home to more than 100 early stage companies advancing bio/pharmaceutical, medical device, consumer and digital health programs. The JLABS facilities will have a total capacity for 225 resident companies once all six are open and operational.

"Houston is already a very active life sciences hub, and we've recently seen a drive to further embrace the industry, establish clear leadership in biotech innovation and close the gap between research and commercialization," said Melinda Richter, head of JLABS. "JLABS is ideally suited to catalyze this result, not only through supporting the development of new healthcare solutions for patients, but also by providing startups with access to the broader JLABS network and its family of incubators."

Texas Medical Center hosts an increasing number of life sciences and biotech companies via commercialization initiatives, such as its Innovation Institute, steadily growing the opportunities for academic and industry partnerships in Houston.

The following companies are the first selected residents of JLABS @ TMC:

  • Beta Cat Pharmaceuticals
  • Icell Kealex Therapeutics
  • IDA Therapeutics
  • IGY Immune Technologies & Life Sciences
  • ImmunoMet Therapeutics
  • Immunophotonics
  • Innovate Wireless Health
  • Medicenna BioPharma
  • Metaclipse Therapeutics
  • NanoMedical Systems
  • Noninvasix
  • Oncomfort
  • Panamab
  • Seremedi
  • TomoWave Laboratories
  • Viracyte

JLABS Quick Fire Challenge winners include:

  • Adhesys Medical
  • Alterna Therapeutics
  • Procyrion
  • Resonant Therapeutics

Johnson & Johnson Innovation has entered into a collaboration with PerkinElmer to outfit the new JLABS @ TMC facility with world-class lab instruments and software as well as to provide training, OneSource Laboratory Services and on-site technical support for the resident companies.

All JLABS locations are accepting applications from biotech, pharmaceutical, medical device, consumer and digital health companies.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing